Clinical Trials for Pulmonary Fibrosis Treatment
Pulmonary fibrosis is a disease that affects the lung tissue by scarring it. Extensive damage to lung tissue causes inefficiency in transferring oxygen to different body parts.
This leads to shortness of breath in the patient, even when they perform normal tasks. In pulmonary fibrosis, severe symptoms such as acute exacerbations can last several days to weeks. Still, patients generally do not return to normal breathing afterward as the disease typically progresses over time.
Most cases of pulmonary fibrosis do not have a clear cause.
Symptoms tend to become worse suddenly and dramatically in some people, while others may experience symptoms worsening over a longer period. One of the key aspects that researchers are interested in is the major factors that rapidly worsen patients’ conditions.
Apart from this, research studies are also being conducted to find better diagnostic methods and improved treatment techniques to alleviate the symptoms of pulmonary fibrosis.
Top Clinical Trials for Pulmonary Fibrosis Treatment
This is our selection of the top clinical trials for pulmonary fibrosis treatment:
1 – Treating People with Idiopathic Pulmonary Fibrosis with the addition of Lansoprazole (TIPAL)
Idiopathic Pulmonary Fibrosis (IPF) causes progressive scarring to the lung tissue and results in coughing and breathlessness. Patients suffering from IPF also exhibit reflux disease symptoms, which cause stomach acid to enter into the lungs and damage them potentially.
As Proton Pump Inhibitors (PPIs) have been effective in stopping stomach acid production, the research is focused on finding its effectiveness in reducing reflux symptoms, such as heartburn, and reducing IPF progression.
This clinical study aims to research if the progression of IPF symptoms can be slowed down with PPIs, particularly focusing on symptoms of reflux that may exacerbate lung damage.
- Study Type – Interventional (Clinical Trial)
- Enrolment – 298 participants
- Allocation – Randomized
- Primary Purpose – Treatment
2 – Study of Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis (IPF)
This study is being conducted to determine the difference in baseline changes with Six Minute Walking Distance (6MWD) when pulmonary rehabilitation (PR) is included to a stable underlying nintedanib therapy in patients suffering from idiopathic pulmonary fibrosis (IPF).
The research also focuses on determining the difference in changes in Quality of Life (QoL) when pulmonary rehabilitation is included in stable underlying nintedanib therapy in patients suffering from IPF.
Another aim of this clinical trial is to evaluate if pulmonary rehabilitation can sustain 6MWD, QoL, and lung function when used alongside stable nintedanib therapy in patients with idiopathic pulmonary fibrosis (IPF).
- Study Type – Interventional (Clinical Trial)
- Enrolment – 19 participants
- Allocation – Randomized
- Primary Purpose – Treatment
3 – Mineralocorticoid Receptor Antagonist and Pulmonary Fibrosis in COVID-19 (SpiroCOVID19)
The SARS 2019 CoV-2 virus causes an acute lower respiratory tract infection. Since it was discovered in 2019, scientists worldwide have focused on finding the proper treatment and vaccine for this disease.
While a significant portion of COVID-19 patients are asymptomatic or have mild symptoms, a smaller percentage develop severe respiratory complications such as respiratory failure, which can be fatal.
This study is focused on evaluating the efficacy of intravenous forms of mineralocorticoid receptor antagonist cenrenoate potassium in treating COVID-19-associated pulmonary fibrosis using the immune system mechanism.
- Study Type – Interventional (Clinical Trial)
- Enrolment – 50 participants
- Allocation – Randomized
- Primary Purpose – Treatment
4 – Colchicine and Post COVID-19 Pulmonary Fibrosis
Pulmonary fibrosis often develops into adult respiratory distress syndrome (ARDS). Around 40% of COVID-19 patients develop ARDS, of which around 20% of cases are severe. Radiographic, clinical, and autopsy reports can show signs of pulmonary fibrosis following a COVID-19 infection, particularly in severe cases.
Existing evidence suggests that pulmonary fibrosis can complicate the COVID-19 infection. Colchicine is an effective anti-inflammatory drug that inhibits the synthesis of tumor necrosis factor-alpha and IL-6, monocyte migration, and the secretion of matrix metalloproteinase-9.
This subdues cytokinesis and chemokinesis secretion and aggregation of in vitro platelets.
- Study Type – Interventional (Clinical Trial)
- Enrolment – 250 participants
- Allocation – Randomized
- Primary Purpose – Treatment
Conclusion
Numerous research studies are conducted every year worldwide to discover new and innovative treatment methods for severe respiratory disorders, such as pulmonary fibrosis.
By participating in these clinical trials, you can contribute to the discovery of effective and efficient pulmonary fibrosis treatment methods.
See Also
Tooth Regeneration Clinical Trials
Where to find paid clinical trials for smokers
Types of Weight Loss Surgery Procedures
Follow us